YolaRX Consultants, Paris, France.
Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.
Curr Heart Fail Rep. 2022 Jun;19(3):146-156. doi: 10.1007/s11897-022-00542-5. Epub 2022 Mar 30.
To quantify the prevalence of asymptomatic pre-heart failure (pre-HF), progression to more severe stages, and associated mortality.
A systematic review was conducted between 01 January 2010 and 12 March 2020 (PROSPERO: CRD42020176141). Data of interest included prevalence, disease progression, and mortality rates. In total, 1030 sources were identified, of which, 12 reported on pre-HF (using the ACC/AHA definition for stage B HF) and were eligible. Prevalence estimates of pre-HF ranged from 11 to 42.7% (10 sources) with higher estimates found in the elderly, in patients with hypertension, and in men. Three studies reported on disease progression with follow-up ranging from 13 months to 7 years. The incidence of symptomatic HF (HF/advanced HF) ranged from 0.63 to 9.8%, and all-cause mortality from 1.6 to 5.4%. Further research is required to investigate whether early detection and intervention can slow or stop the progression from asymptomatic to symptomatic HF.
定量无症状前心力衰竭（pre-HF）的患病率、向更严重阶段的进展以及相关死亡率。
在 2010 年 1 月 1 日至 2020 年 3 月 12 日之间进行了系统综述（PROSPERO：CRD42020176141）。感兴趣的数据包括患病率、疾病进展和死亡率。总共确定了 1030 个来源，其中 12 个报告了使用 ACC/AHA 心力衰竭 B 期定义的 pre-HF，符合条件。pre-HF 的患病率估计值在 11%至 42.7%（10 个来源）之间，在老年人、高血压患者和男性中患病率更高。三项研究报告了疾病进展情况，随访时间从 13 个月到 7 年不等。有症状心力衰竭（HF/advanced HF）的发生率在 0.63%至 9.8%之间，全因死亡率在 1.6%至 5.4%之间。需要进一步研究以调查早期检测和干预是否可以减缓或阻止无症状向有症状心力衰竭的进展。
